|
PALO ALTO, Calif., Dec. 27 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it has initiated a license and development partnership with Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) for AZ-003 (Staccato(R) fentanyl) and the fentanyl class of molecules for North America. Currently in Phase 1 clinical development, AZ-003 is a hand-held drug device that uses Alexza's proprietary Staccato system inhalation technology to deliver fentanyl for the treatment of breakthrough pain in cancer and non-cancer patients.
SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will announce early positive data from the ongoing Phase 1-2 trial of the company's selective androgen receptor modulator, MDV3100, in hormone refractory prostate cancer before the markets open on Monday, November 5, 2007. A conference call and live webcast will be held at 8:30 a.m. Eastern Time on Monday to discuss these data.
SAN CARLOS, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2007 on Wednesday, November 7, 2007, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call for analysts and investors beginning at 5:00 p.m. Eastern Time (ET).
Investors can access the press release and a live audio-only Webcast of the conference call through a link that is posted on the Investor Relations section of the Nektar website: http://www.nektar.com/. The web broadcast of the conference call will be available for replay through November 21, 2007.
PDI, Inc. (NASDAQ:PDII), a provider of commercialization services to the biopharmaceutical industry, today announced that it will release its third quarter 2007 financial results on Thursday, November 8, 2007 after the market close.
PDI will host an investment community conference call beginning at 4:30 p.m. Eastern time on November 8, 2007 to discuss these results and to answer questions.
To participate in the live conference call by telephone, please dial (866) 644-4654 from the U.S., or for international callers, please dial (706) 634-8407.
Bio-Imaging Technologies, Inc. (NASDAQ: BITI) will release its financial results for the third quarter ended September 30, 2007 on Wednesday, November 7, 2007.
Management of Bio-Imaging Technologies, Inc. will host a conference call on the same day at 11 a.m. EST to discuss the company's financial results and achievements. Those who wish to participate in the conference call may telephone (888) 335-6674 from the U.S. or (973) 321-1100 for international callers, passcode 9373493 approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioimaging.com. A digital replay will be available by telephone for two weeks and may be accessed by dialing (877) 519-4471, from the U.S., or (973) 341-3080, for international callers, passcode 9373493. The replay will also be on the website under "Investor Relations" at www.bioimaging.com for two weeks.
RANCHO CORDOVA, Calif., Nov. 1 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that harvest, process, store, and administer therapeutic doses of adult stem cells for treatment of disease and injury, announced today it will report financial results for the fiscal first quarter ended September 30, 2007, on Thursday, November 8, 2007.
Company's Conference Call and Webcast
Management will host a conference call Thursday, November 8, 2007 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal first quarter financial results.
WALTHAM, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a global leader in rapid point-of-care diagnostic products, today announced its financial results for the quarter ended September 30, 2007.
In the third quarter of 2007, the Company recorded net revenue of $237.6 million compared to net revenue of $144.9 million in the third quarter of 2006. The revenue increase was primarily due to increased sales in our Professional Diagnostic segment contributed by businesses acquired, which contributed $94.3 million of the increased product revenue, offset by a decrease of $17.1 million in revenue as compared to the prior year's quarter as a result of our second quarter of 2007 formation of a joint venture for our Consumer Diagnostics business with the Procter & Gamble Company.
Yes, our conference calling service is free, and there is no catch. BV FreeConferencing wonæ° charge you anything for using our free conference calling service anytime, anywhere. Everyone who participates in your free conference calls, including yourself, will dial a regular toll number (not toll-free/1-800). Any cost incurred is dependent on each participantæ¯ long-distance plan. The conference calling service itself is absolutely free. You can use it as often as you want, for as long as you like. There are no strings attached.
Use BV FreeConferencing as often as you like. You can host as many free conference calls as you want with your account. The conference calling codes you receive when you sign up are yours to use anytime you need free conference calling.
No, your personal information will not be sold or distributed to any third party. Basement Ventures may send you an occasional email with information about our website, new service offerings and changes or updates on our network.
|
